Literature DB >> 15144528

Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.

K Janetzko1, L Lin, H Eichler, V Mayaudon, J Flament, H Klüter.   

Abstract

BACKGROUND AND OBJECTIVES: The INTERCEPT Blood System for Platelets utilizes amotosalen-HCl (S-59) in combination with ultraviolet A (UVA) light to inactivate viruses, bacteria, protozoa and leucocytes that may contaminate platelet concentrates (PCs). To facilitate implementation of this technique into routine blood bank manufacturing procedures, this study evaluated the impact of different time settings of photochemical treatment on in vitro platelet function.
MATERIALS AND METHODS: Platelets derived from apheresis (6.5-7.0 x 10(11) platelets) were resuspended in 240 ml of autologous plasma and 360 ml of platelet additive solution (PAS III) and split into two equal-sized PC units. Whereas one unit was not treated, the other was treated with 150 microm amotosalen and 3 J/cm2 UVA light followed by a compound adsorption device (CAD) step for reduction of residual amotosalen and photoproducts. In a first series of experiments (arm A, n = 7), PC units were photochemically treated after an overnight storage period of 16-23 h followed by a CAD step of 4 h. In a second series (arm B, n = 8), photochemical treatment occurred after a short storage time of 4 h with a subsequent CAD step of 16 h. Platelet function was evaluated by assaying blood gas analysis, glucose and lactate concentration, lactate dehydrogenase (LDH), hypotonic shock response (HSR) and the expression of CD62p, over a period of 7 days.
RESULTS: Neither of the photochemical treatment procedures showed differences for pH, pCO2, pO2, HCO3, glucose consumption or platelet activation until the end of day 7. Increased lactate values detected for the treated units of arm A at the end of the storage period were independent from the PCT time setting.
CONCLUSIONS: Photochemical pathogen inactivation with different initial resting periods between 4 and 23 h, and different CAD steps of 4 and 16 h, had no influence on the platelet in vitro function during 7 days of storage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15144528     DOI: 10.1111/j.0042-9007.2004.00419.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  8 in total

Review 1.  Economics of pathogen inactivation technology for platelet concentrates in Japan.

Authors:  Ulf Staginnus; Laurence Corash
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

2.  Frequency of detection of bacterial DNA in whole blood of donors.

Authors:  N A Fedorov; A A Yolovl; E B Zhiburt; Yu S Sukhanov; A N Kruglov; A V Stonogin; S A Golosova; E G Cherkasov; M P Grishaev; E N Fedorov; A S Turgiev
Journal:  Dokl Biol Sci       Date:  2005 May-Jun

3.  In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step.

Authors:  Mélanie Abonnenc; Giona Sonego; Julie Kaiser-Guignard; David Crettaz; Michel Prudent; Jean-Daniel Tissot; Niels Lion
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

4.  Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system.

Authors:  Americo Cicchetti; Silvia Coretti; Francesco Sacco; Paolo Rebulla; Alessandra Fiore; Filippo Rumi; Rossella Di Bidino; Luz I Urbina; Pietro Refolo; Dario Sacchini; Antonio G Spagnolo; Emanuela Midolo; Giuseppe Marano; Blandina Farina; Ilaria Pati; Eva Veropalumbo; Simonetta Pupella; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2018-09-03       Impact factor: 3.443

5.  The assessment of platelet function by thromboelastometry as a point-of-care test to guide Intercept-treated platelet support in hemato-oncological patients and hematopoietic stem cell transplantation recipients.

Authors:  Gerda C Leitner; Markus Ho; Alexander Tolios; Georg Hopfinger; Werner Rabitsch; Philipp Wohlfarth
Journal:  Transfusion       Date:  2020-04-22       Impact factor: 3.157

6.  [Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP].

Authors:  C Naegelen; H Isola; D Dernis; J-P Maurel; R Tardivel; S Bois; C Vignoli; J-P Cazenave
Journal:  Transfus Clin Biol       Date:  2009-05-13       Impact factor: 1.406

7.  Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function.

Authors:  Abdimajid Osman; Walter E Hitzler; Claudius U Meyer; Patricia Landry; Aurélie Corduan; Benoit Laffont; Eric Boilard; Peter Hellstern; Eleftherios C Vamvakas; Patrick Provost
Journal:  Platelets       Date:  2014-04-21       Impact factor: 3.862

Review 8.  Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic.

Authors:  Gines Escolar; Maribel Diaz-Ricart; Jeffrey McCullough
Journal:  Transfusion       Date:  2021-12-06       Impact factor: 3.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.